Healio Minute

In this edition, FDA accepts new drug application for Eluminex, most mentors in vitreoretinal subspecialty are men and more. Read the full coverage here:

FDA accepts investigational new drug application for Eluminex DME treatment

Most mentors in vitreoretinal subspecialty are men

Carotid artery stenosis linked to retinal changes in patients with diabetic retinopathy

AI-assisted technology makes retinal imaging 100 times faster, with greater contrast

FDA clears fully autonomous AI for portable diabetic retinopathy screening

References:

Das V, et al. Commun Med. 2024;doi:10.1038/s43856-024-00483-1.

Lee CY, et al. BMC Ophthalmol. 2024;doi:10.1186/s12886-024-03391-z.

Press Release

Press Release

Shah SM, et al. Demographics and productivity trends among academically affiliated female vitreoretinal specialists in the United States. Presented at: Real World Ophthalmology; April 27, 2024 (virtual meeting).

In this edition, FDA approves Selarsdi as Stelara biosimilar, deucravacitinib improves 'broad range' of patient-reported outcomes and more. Read the full coverage here:

FDA approves Selarsdi as Stelara biosimilar for psoriasis, psoriatic arthritis

Deucravacitinib improves 'broad range' of patient-reported psoriatic arthritis outcomes

Advanced therapy not enough for nearly 75% of Canadian patients with psoriatic arthritis

New EULAR recommendations for psoriatic arthritis urge biologics after methotrexate failure

Dactylitis, enthesitis resolution linked to less pain, fatigue in guselkumab-treated PsA

References:

Gladman DD, et al. J Rheumatol. 2024;doi:10.3899/jrheum.2023-0716.

Gossec L, et al. Ann Rheum Dis. 2024;doi:10.1136/ard-2024-225531.

Press Release

Rahman P, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-06921-8.

Strand V, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25333.

In this edition, durvalumab improves survival in limited-stage small cell lung cancer, most adults do not test homes for radon exposure and more. Read the full coverage here:

Durvalumab improves survival in limited-stage small cell lung cancer

Survey: Most adults do not test homes for radon exposure, unconcerned about risks

FDA fast tracks investigational bispecific therapy for aggressive lung cancer

Research shows complexity of shared decision-making about lung cancer screening

Keytruda-Lynparza combination misses survival targets in phase 3 lung cancer trial

References:

Núñez E, et al. Ann Fam Med. 2024;doi:10.1370/afm.3081.

Press Release

Press Release.

Press Release

Press Release

In this edition, PALADIN study navigates IOP-lowering surgery in DME patients, small-molecule eye drop well-tolerated as treatment for retinal vascular diseases and more. Read the full coverage here:

PALADIN study: Navigating IOP-lowering surgery in DME patients for optimal outcomes

Small-molecule eye drop safe, well-tolerated as treatment for retinal vascular diseases

VIDEO: Reduction of vascular leakage, hyperreflective foci greater with faricimab

VIDEO: Real-world study shows durability of fluocinolone acetonide implant in DME

Early safety, efficacy results positive for Restoret in DME, wet AMD

References:

Chin Yee DS, et al. Outcomes in eyes requiring IOP-lowering surgery after treatment with the 0.19-mg fluocinolone acetonide implant for DME: The PALADIN study. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.

Graff JM. Biomarkers for vascular stability and inflammation demonstrate the benefit of dual Ang-2/VEGF-A inhibition with faricimab phase 3 trials in DME. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.

Minaker S. The 0.19mg fluocinolone acetonide (FAc) implant reduces the recurrence of edema by providing long-term control of retinal thickness variability in patients with DME: The 3-year PALADIN study. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.

Press Release

Press Release

In this edition, race identified as risk factor for VTE, FDA approves Rybrevant for treatment of non-small cell lung cancer and more. Read the full coverage here:

Race identified as risk factor for VTE after pulmonary resection for lung cancer

FDA approves Rybrevant for treatment of non-small cell lung cancer

Behavioral health disorders have a 'big impact' on cancer surgery outcomes

Optimizing immunotherapy, biomarker testing vital to progress in lung cancer treatment

FDA approves Tagrisso plus chemotherapy for EGFR-mutated non-small cell lung cancer

References:

Axtell AL, et al. Ann Thorac Surg. 2024;doi:10.1016/j.athoracsur.2024.01.005.

Katayama ES, et al. J Am Coll Surgeons. 2024;doi:10.1097/XCS.0000000000000954.

Press Release

Press Release

Press Release

In this edition, blood test for lung cancer patients who may benefit from further immunotherapy, invasive procedures following lung cancer screenings and more. Read the full coverage here:

Blood test identifies those with lung cancer who may benefit from further immunotherapy

Invasive procedures rarely follow false-positive lung cancer screenings

Study: Positive associations found between smoking and risk of ALS

Major cancer surgery associated with 'elevated' risk for venous thromboembolism

Quality improvement project bridges 'significant gap' in biomarker testing for lung cancer

References:

Anagnostou A, et al. Nat Med. 2023;doi:10.1038/s41591-023-02598-9.

Björklund J, et al. JAMA Netw Open. 2024;doi:10.1001/jamanetworkopen.2023.54352.

Healio Interviews

Kim YH, et al. Tob Induc Dis. 2024;doi:10.18332/tid/17531.

Manyak A, et al. CHEST. 2023;doi:10.1016/j.chest.2023.02.010.

In this edition, FDA places hold on cell therapy trial after patient death, selpercatinib delivers superior outcomes and more. Read the full coverage here:

FDA places hold on trial of cell therapy for lung cancer after patient death

Selpercatinib delivers superior outcomes, may 'reduce the burden of NSCLC'

First-line immunotherapy benefits patients of all races with NSCLC equally

Never-smoker lung cancer survivors require targeted surveillance

Cemiplimab plus chemotherapy improves outcomes in metastatic NSCLC

References:

Baramidze A, et al. Abstract 1495P. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.

Choi E, et al. JAMA Netw. Open. 2023;doi:10.1001/jamanetworkopen.2023.43278.

Lee M, et al. J. Natl Compr Canc Netw. 2023;doi:10.6004/jnccn.2023.7064

Press Release

Zhou C, et al. N Engl J Med. 2023;doi:10.1056.NEJMoa2309457.

In this edition, an advocacy group petitions the FDA for stronger safety warnings for Botox, melanoma regression is associated with improved prognosis and more. Read the full coverage here:

Advocacy group petitions FDA for stronger safety warnings for Botox, related drugs

Melanoma regression associated with improved prognosis

Phase 4 results show Vtama cream efficacious in head, neck plaque psoriasis

Isotretinoin not associated with increased risk for suicide, psychiatric conditions

Tape strips may identify hidradenitis suppurativa in lesional, nonlesional skin

References:

Navrazhina K, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.11.048.

Press Release

Press Release

Tan NKW, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.4579.

Wagner NB, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.11.040.

In this edition, allergic illnesses in children may be inherited from mothers; addressing needs of Muslim patients in dermatology; YouTube content on topical steroid withdrawal exhibits poor reliability and more. Read the full coverage here:

Atopic dermatitis, other allergic illnesses in children may be inherited from mothers

Addressing needs of Muslim patients in dermatology

YouTube content on topical steroid withdrawal exhibits poor reliability, quality

RelabotulinumtoxinA demonstrates rapid onset, durability for frown lines, crow's feet

Puberty, skin of color, weight associated with acne prevalence among adolescents

References:

Chiesa Fuxench ZC, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.11.013.

El-Banna G, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.4439.

McCormick E, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.C7443.

Press Release

Witkam WCAM, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.10.062.

In this edition, dermatologists 'uniquely positioned' to aid human trafficking victims; FDA approves Cosentyx for hidradenitis suppurativa and more. Read the full coverage here:

Dermatologists 'uniquely positioned' to recognize, aid human trafficking victims

FDA approves Cosentyx as first IL-17A inhibitor for hidradenitis suppurativa

FDA approves Stelara biosimilar for treatment of psoriasis, multiple inflammatory diseases

RECELL system efficacious in vitiligo repigmentation

Isotretinoin efficacious in seborrheic dermatitis treatment

References:

Elbuluk N. Optimizing melanocyte cell transplant procedure for treatment of vitiligo. Presented at: American Society for Dermatologic Surgery Annual Meeting; Nov 1-5, 2023; Chicago.

Kourosh S. The role of dermatologic surgeons in advocating for those affected by human trafficking. Presented at: American Society for Dermatologic Surgery Annual Meeting; Nov 1-5, 2023; Chicago.

Press Release

Press Release

Tan MG, et al. Isotretinoin for the management of moderate to severe seborrheic dermatitis. Presented at: American Society for Dermatologic Surgery Annual Meeting; Nov 1-5, 2023; Chicago.